Search - tctmd.com

Displaying 101 - 120 of 159

Sort: Relevancy | Date

Presentation TCT 2015

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Presenter: John A. Bittl, Robert A. Harrington, David Erlinge

October 12, 2015

Presentation TCT 2015

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

Presenter: John A. Bittl, Robert A. Harrington, Harvey D. White

October 12, 2015

Presentation TCT 2015

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Presenter: John A. Bittl, Robert A. Harrington, Jorge F. Saucedo

October 12, 2015

Presentation TCT 2015

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Presenter: John A. Bittl, Robert A. Harrington, Philippe Gabriel Steg

October 12, 2015

Presentation TCT 2015

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Presenter: John A. Bittl, Robert A. Harrington, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Focused Commentary

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Roxana Mehran

October 12, 2015

Presentation TCT 2015

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, Marco Valgimigli

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

Presentation TCT 2015

DAPT Duration After DES: Does 1 Size Fit All?

Presenter: Robert A. Harrington, Gregg W. Stone, David J. Cohen, John A. Bittl

October 12, 2015

Presentation TCT 2015

The 10 Most Common Statistical Mistakes and Misinterpretations I See Again and Again

Presenter: Robert A. Harrington, Pascal Vranckx, Sanjay Kaul

October 11, 2015

Presentation TCT 2015

When Is the Primary Endpoint Not Enough? Pitfalls in Primary Endpoint Selection and Assumptions, Power, and More

Presenter: Robert A. Harrington, Pascal Vranckx

October 11, 2015

Presentation TCT 2015

How to Assess the Quality of Evidence From Peer-Reviewed Manuscripts: The Statistical Reviewers Vantage Point

Presenter: Robert A. Harrington, Pascal Vranckx, Jan Tijssen

October 11, 2015

News Conference News ACC 2015

BEST: Due to Less TVR, CABG Still Favored Over PCI in Patients with Multivessel Disease

L.A. McKeown

March 16, 2015

News Conference News ACC 2015

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

Todd Neale

March 14, 2015

News Conference News AHA 2014

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

November 16, 2014

News Conference News AHA 2014

DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation

Yael L. Maxwell

November 16, 2014

Presentation TCT 2014

Keynote Lecture II: Clinical Research in the United States Current Realities and How the Tide Can Turn

Presenter: Matthew G. Hillebrenner, Roxana Mehran, Aaron V. Kaplan, Robert A. Harrington

September 15, 2014

Presentation TCT 2014

Cangrelor II: New Data from the FDA Advisory Board Panel

Presenter: Christian W. Hamm, Franz-Josef Neumann, Philippe Généreux, Robert A. Harrington

September 15, 2014

News Conference News TCT 2014

Post-procedural Consent in STEMI Trials Debated

September 15, 2014

Presentation TCT 2014

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Presenter: Robert A. Harrington, Ajay J. Kirtane, Thomas D. Stuckey, Frederick Feit

September 14, 2014

Advertisement

Procedural Anticoagulants in Sweden: Results From the SCAAR Registry and Rationale for VALIDATE-SWEDEHEART

Cangrelor + Bivalirudin: The Perfect Marriage or a Forced Union?

What, if Any, Is the Role for LMWH and GP IIb/IIIa Inhibitors in ACS or During PCI?

Bivalirudin Pearls: Necessity With Radial Access, Infusion Dose and Duration, Use in CKD, and More

Bivalirudin vs Heparin in ACS: The New Data MATRIX Antithrombin Results

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies Focused Commentary

Periprocedural Antiplatelet Therapy: Agent(s) of Choice, Oral vs IV, and Loading Strategies

DAPT Duration After DES: Does 1 Size Fit All? Focused Commentary

DAPT Duration After DES: Does 1 Size Fit All?

The 10 Most Common Statistical Mistakes and Misinterpretations I See Again and Again

When Is the Primary Endpoint Not Enough? Pitfalls in Primary Endpoint Selection and Assumptions, Power, and More

How to Assess the Quality of Evidence From Peer-Reviewed Manuscripts: The Statistical Reviewers Vantage Point

BEST: Due to Less TVR, CABG Still Favored Over PCI in Patients with Multivessel Disease

Long-Term DAPT with Ticagrelor Reduces Ischemic Risk, Ups Bleeding in MI Patients

Ezetimibe Proves Clinical Benefit on Top of Statin Therapy

DAPT Study Shows Benefit of Long-Term Treatment After DES Implantation

Keynote Lecture II: Clinical Research in the United States Current Realities and How the Tide Can Turn

Cangrelor II: New Data from the FDA Advisory Board Panel

Post-procedural Consent in STEMI Trials Debated

Does Cilostazol Have a Role as an Antiplatelet Agent in the Contemporary DES Era (and in Triple Therapy Decisions)?

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content